📰 Want to stay informed with all the latest news & updates from @remedi4all? 🖊️ Sign up to our Newsletter 🗞️ to find out how we are contributing to advance #MedicinesRepurposing. 📤 Subscribe here: loom.ly/biTlp_g

🚀 Exciting news for researchers! 🚀 REMEDi4ALL partners have launched an #OpenAccess catalogue packed with #DrugRepurposing resources 💊💻 for basic and clinical research!🔬 Discover more with our comprehensive user-guide📄 and video walkthrough📹 ➡️[loom.ly/e0bBYjc]

🗞️Newsflash! Oncologie Up-to-date recently interviewed REMEDi4ALL partners Dr Heleen van der Meer and Dunja Huijbers (ZonMw) about #REMEDi4ALL goals🎯and #DrugRepurposing barriers💊. Read the full article here➡️ [loom.ly/WkJ2Uos] Anticancer Fund EATRIS Teamit

Our recent Multi-stakeholder Meeting focused on "Ensuring Patient Centricity in Osteogenesis Imperfecta (OI) Research" with over 80 participants discussing & developing strategies to ensure patient voices are at the forefront of OI research. 👉 More here: remedi4all.org/2nd-remedi4all…

"Inspiring. Intense. Enjoyable" Find out more about insights gained from the 1st #REMEDi4ALL Hackathon💻 where REMEDi4ALL early career researchers explored the drug repurposing pathway and devised #DrugRepurposing development plans for NDDs.🔬 ⬇️loom.ly/92xfVAE⬇️

Join the 'Medicines Reimagined' Forum, where enthusiasts and experts in drug repurposing unite! Connect, collaborate, share insights, and explore the challenges and successes in the #DrugRepurposing field. 👉Visit: remedi4all.org/stakeholder-fo… #REMEDi4ALL

REMEDi4ALL pushes for change by addressing roadblocks throughout the repurposing journey. We've compiled case studies to demystify #DrugRepurposing. Learn about PRO Spectrum and how a breast cancer drug, Alpelisib, has been repurposed for this condition remedi4all.org/case-studies/

The REMEDi4ALL Funders Network, led by ZonMw & Anticancer Fund, unites global research funders committed to advancing #DrugRepurposing. Over 30 organisations have joined, shaping the future of medicine for patient benefit. ➡️ More about the network here: remedi4all.org/funders-networ…

Attention researchers! Have you seen the new #DrugRepurposing resource available from #REMEDi4ALL partners?🔬👥 The #R4ALL in-silico drug repurposing catalogue collates relevant tools, databases and methods in an easy-to-use platform💻. ➡️ More here: remedi4all.org/in-silico-drug…

Exciting #DrugRepurposing news! #REMEDi4ALL partners FIMM HelsinkiUni have launched RepurposeDrugs, an Open Access repository using machine learning to predict drug interactions and combinations to open paths for innovative treatments💊💻. Learn more here ➡️[loom.ly/A8I_OMM]

Want to find out more about #REMEDi4ALL researchers?🔬 Read about PhD student Kristen Nader's (FIMM HelsinkiUni) #DrugRepurposing research, career goals and chosen superpower in the latest edition of Early Career Researcher Insights⬇️ [loom.ly/s5cOAyY]

#DrugRepurposing has great potential to benefit patients. To achieve this, we need to foster innovation every step of the way. Johanna Hutching Fraunhofer ITMP echoed this sentiment at the International Drug Repurposing Conference #iDR24. ➡️More here: remedi4all.org/idr-conference…

At #iDR24, the annual REMEDi4ALLL International Drug Repurposing Conference, we were joined by Sanford Simon (Rockefeller University). Sanford highlighted the importance of multi-stakeholder engagement & collaboration in #DrugRepurposing. ➡️More on #iDR here: remedi4all.org/idr-conference…

The #REMEDi4ALL website now has examples of #DrugRepurposing, such as the use of Metformin (used to treat type II diabetes) to lower the risk of cancer for Li–Fraumeni patients. 👉 Find out more about this case, & others, here: remedi4all.org/case-studies

Looking for a tool to help you find new #DrugRepurposing applications? Check out the #REMEDi4ALL in-silico drug repurposing catalogue📖 packed with tools, methods & databases for #DrugRepurposing researchers🧑‍🔬 Get started ➡️ remedi4all.org/in-silico-drug… remedi4all.org/in-silico-drug…

📣New publication!📣 REMEDi4ALL partners @EURORDIS just published in Frontiers in Medicine. Claudia Fuchs and team explore drug repurposing for Rett and Rett-like syndromes—rare neurodevelopmental disorders with limited treatment options. Read more ➡️ loom.ly/c5_WApM

📃 New REMEDi4ALL publication! Our partners at @FIMM have just published in Bioinformatics, introducing a new computational method aimed at predicting the activities of drugs across >1400 human proteins! Read the full article here➡️ [academic.oup.com/bioinformatics…].]

At #iDR24 Beacon for Rare Diseases CEO Rick Thompson talked about the importance of overcoming barriers to get the right treatments to patients, faster. #REMEDi4ALL promotes multistakeholder collaborations with valuable patient insights👥. More about #iDR here➡️ remedi4all.org/idr-conference…

The #iDR conference series unites #DrugRepurposing stakeholders to share results, spark ideas, and prioritise patient perspectives👥. Mary Rose Roberts, COO at Beacon for Rare Diseases, highlights putting patients first in #DrugRepurposing. More on #iDR here ➡️ remedi4all.org/idr-conference…

Looking for a tool to discover drug repurposing applications within your field of research? The new REMEDi4ALL in-silico catalogue offers #OpenAccess databases on compounds, drug-target, and drug-disease interactions in one place. Explore more here ➡️ remedi4all.org/in-silico-drug…